 1.To evaluate the safety and feasibility of the sequential use of a DNA methyltransferase DNMT inhibitor decitabine with a targeted biological agent against EGFR panitumumab for KRAS wild type tumors in the second or third line treatment of advanced metastatic colorectal cancer. 